The literature supports various pathophysiologies in individuals affected with autism spectrum disorder (ASD), including cerebral hypoperfusion, inflammation, mitochondrial dysfunction and oxidative stress. It has been hypothesized that children affected with ASD might benefit from Hyperbaric oxygen treatment (HBOT) owing to the increase in cerebral perfusion occurring during treatment. Here I present my theories on potential cannabinoid synergy with hyperbarics.
The cell-danger response and endocannabinoid signaling pathways have been described as possible key elements in the pathophysiology of microglia driven neuroinflammation, with resulting behavioral problems associated with ASD.
With the growing body of evidence in the literature that describes beneficial phytocannabinoid effects in patients affected with ASD, we highlight the principle mechanisms of a novel concept, e.g. phytocannabinoid-hyperbaric-oxygen synergy and its role in paving the way for faster and lasting clinical benefits. HBOT is approved for several clinical disorders including decompression sickness, gas gangrene, cyanide poisoning and diabetic wounds. Inhalation of above-atmospheric oxygen might result in an elevation of arterial partial pressure of oxygen, leading to increased oxygen delivery to the brain.
HBOT might also have anti-inflammatory properties due to the reduction of pro-inflammatory cytokines (tumor necrosis factor–α, interferon-γ, and interleukins 1 and 6). Furthermore, HBOT might improve mitochondrial dysfunction, as well as up-regulate the production of antioxidant enzymes. While some studies suggest improved cerebral perfusion, others showed decreased markers of inflammation and did not worsen oxidative stress markers in children with ASD. In the reviewed studies, HBOT had minimal adverse effects and was well tolerated.
Most of the reviewed studies relied on changes in behavioral measurements, which may lag behind physiological changes. In our protocol, we utilize different ATAs in monoplace chambers for all ASD children. The molecular collusion of hyperbaric oxygen and phytocannabinoids suggests synergistic properties, aiding in anti-inflammation, detoxification, improved synaptic plasticity and central nervous system homeostasis.
In autism, major protective brain mechanisms become interrupted and neuroinflammation emerges. A variety of toxins are responsible for the consequential great demand for neuronal protection. This is where cannabis science comes in to play. And guess what? It’s backed by a lot of solid research. I can vouch for this: I’ve personally gathered cannabis papers for autism in the original Michigan petition 3 years ago and helped support 4 states’ petition as well. It’s a banker’s box full of the finest research papers.
John’s Hopkins University found a 25% reduction of overall annual mortality from opioids due to state cannabis program implementations. The science speaks volumes. It is time to de-schedule cannabis, not primarily to have states cash in billions of dollars, but to benefit the ones who really need need it: the patients who suffer and are dying of mostly ineffective and dangerous pharmaceutical intervention.
I want to thank Del Bigtree for creating the platform for the conversation and inviting me to help spread awareness on the cannabis science for autism spectrum disorders.
The endocannabinoid system plays part in the pathophysiology of autism. Protective brain mechanisms are interrupted and neuroinflammation occurs. Organophosphates are potent inhibitors of crucial brain enzymes. The systemic consequences of defective microglial signaling, nagalase surges, and GcMAF metabolism are interconnected into the basic idea that autism is an environmentally triggered neuroinflammatory condition.
When we dive deep into brain mechanisms in autism, you realize that localized brain tissue is inflamed from foreign substances. There is a plethora of evidence in the scientific literature that is inflammation, mostly in the cerebellum of the brain, is triggered by pesticides and herbicides, aluminum and other adjuvants in vaccines, human DNA and viruses. The dynamics of this injury, as well as potential anti-inflammatory therapies, are discussed in my speech (video above) at AutismOne, 5/27/2017.
View my entire presentation slides as well.